192 related articles for article (PubMed ID: 27873026)
21. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous and sustained remission of intractable myasthenia gravis and focal segmental glomerulosclerosis with tacrolimus treatment.
Chung S; Park CW; Song J; Kim JA; Shin SJ; Chang YS
Clin Nephrol; 2008 Jul; 70(1):59-61. PubMed ID: 18793550
[TBL] [Abstract][Full Text] [Related]
24. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
26. Safety of tapering tacrolimus dose in patients with well-controlled anti-acetylcholine receptor antibody-positive myasthenia gravis.
Nishida Y; Takahashi YK; Kanai T; Nose Y; Ishibashi S; Sanjo N; Uzawa A; Oda F; Ozawa Y; Kuwabara S; Noguchi E; Suzuki S; Nakahara J; Suzuki N; Ogawa T; Yokoyama K; Hattori N; Konno S; Fujioka T; Kawaguchi N; Hatanaka Y; Sonoo M; Kaneko J; Ogino M; Nishiyama K; Nomura K; Yokota T
Eur J Neurol; 2020 Jan; 27(1):100-104. PubMed ID: 31309642
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.
Duan W; Peng Y; Jin W; Ouyang S; Yang H
J Immunol Res; 2021; 2021():9138548. PubMed ID: 34845439
[TBL] [Abstract][Full Text] [Related]
28. A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis.
Ahn SW; Joo IS; Kim BJ; Sung JJ; Kang SY; Oh J; Minn YK; Suh BC; Oh SY; Hong YH; Nam TS; Seok JI; Park YE; Shin HY; Cho EB; Shin JY; Seok HY; Park JS; Min JH; Seok JM; Kim BJ
J Neurol Sci; 2017 Aug; 379():271-275. PubMed ID: 28716258
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of a 2-year-old girl with intractable myasthenia gravis using tacrolimus.
Kakisaka Y; Haginoya K; Yokoyama H; Ishitobi M; Wakusawa K; Sato I; Togashi N; Kitamura T; Fukuyo N; Yoshihara Y; Iinuma K
Brain Dev; 2006 Sep; 28(8):534-6. PubMed ID: 16564661
[TBL] [Abstract][Full Text] [Related]
30. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
[TBL] [Abstract][Full Text] [Related]
31. [A child with generalized myasthenia gravis successfully treated with tacrolimus].
Goto T; Mori M; Yamagata T; Mizuguchi M; Momoi MY
No To Hattatsu; 2007 Jul; 39(4):300-3. PubMed ID: 17633089
[TBL] [Abstract][Full Text] [Related]
32. Clinical study of FK506 in patients with myasthenia gravis.
Konishi T; Yoshiyama Y; Takamori M; Yagi K; Mukai E; Saida T;
Muscle Nerve; 2003 Nov; 28(5):570-4. PubMed ID: 14571458
[TBL] [Abstract][Full Text] [Related]
33. Low-dose tacrolimus for intractable myasthenia gravis.
Yoshikawa H; Mabuchi K; Yasukawa Y; Takamori M; Yamada M
J Clin Neurosci; 2002 Nov; 9(6):627-8. PubMed ID: 12604270
[TBL] [Abstract][Full Text] [Related]
34. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.
Yoshikawa H; Kiuchi T; Saida T; Takamori M
J Neurol Neurosurg Psychiatry; 2011 Sep; 82(9):970-7. PubMed ID: 21784757
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study.
Nagane Y; Utsugisawa K; Obara D; Kondoh R; Terayama Y
Eur Neurol; 2005; 53(3):146-50. PubMed ID: 15900097
[TBL] [Abstract][Full Text] [Related]
36. Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis.
Ponseti JM; Gamez J; Vilallonga R; Ruiz C; Azem J; López-Cano M; Armengol M
Eur J Cardiothorac Surg; 2008 Nov; 34(5):1062-7. PubMed ID: 18760934
[TBL] [Abstract][Full Text] [Related]
37. [Clinical effect of tacrolimus in the treatment of myasthenia gravis in children].
Li JW; Fang F; Ren XT; Zhang WH; Yang XY; Ren CH; Gong S; Lyu JL; Wang XH; Wang X; Wu HS; Ding CH
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Sep; 22(9):964-969. PubMed ID: 32933627
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
39. [The clinical efficacy and safety of tacrolimus in patients with myasthenia gravis].
Chen YP; Wang W; Wang ZK; Wei DN; Zhang J
Zhonghua Nei Ke Za Zhi; 2013 Jul; 52(7):567-9. PubMed ID: 24266997
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis.
Nagappa M; Netravathi M; Taly AB; Sinha S; Bindu PS; Mahadevan A
J Clin Neurosci; 2014 Nov; 21(11):1909-14. PubMed ID: 25043165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
